Allergan Inc (AGN) 229.49 $AGN
Loeb adds Citigroup, Alibaba, AIG stakes; drops FedEX
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:22PM CST
FDX: 176.47 (+0.17), AGN: 229.49 (+1.87), C: 51.20 (+0.31), EMC: 27.99 (+0.12), AIG: 53.96 (+1.51), BABA: 89.05 (+1.95)
Ackman vs. Icahn: How Two Billionaires, Former Adversaries, Stack Up
at The Street - Fri Feb 13, 10:14AM CST
More than two years have passed since Icahn and Ackman's epic CNBC blowout. Though they've since called a truce, it's worth looking at how these two billionaires stack up today.
AGN: 229.49 (+1.87), HLF: 32.78 (-0.84), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), EBAY: 56.47 (+1.73), GCI: 34.77 (-0.07), IEP: 100.21 (+0.28), MTW: 21.86 (+0.34), AAPL: 127.08 (+0.62)
UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 17, 2015
Business Wire - Thu Feb 12, 3:08PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who sold Allergan, Inc. ("Allergan" or the "Company"
(NYSE:AGN) securities between February 25, 2014 and April 21, 2014.
AGN: 229.49 (+1.87)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Collagen and HA-Based Biomaterials - Global Strategic Business Report 2015: Increasing Preference for Shorter and Convenient Treatment Options
M2 - Wed Feb 11, 2:30PM CST
Research and Markets (http://www.researchandmarkets.com/research/hsppk2/collagen_and) has announced the addition of the "Collagen and HA-Based Biomaterials - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Collagen and HA-Based Biomaterials in US$ Thousands by the following Product Segments: Collagen-based Biomaterials (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, Wound Dressings), and Hyaluronic Acid-based Biomaterials (Viscosupplements, Viscoelastics, and Facial Aesthetic Dermal Fillers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 55 companies including many key and niche players such as: - Abbott Medical Optics, Inc. (US) - Alcon Laboratories, Inc. (US) - Allergan, Inc. (US) - Anika Therapeutics, Inc. (US) - Bausch & Lomb, Inc. (US) - Collagen Solutions Plc. (UK) - Galderma (Switzerland) - Genzyme (US) - Lifecore Biomedical, LLC (US) - Seikagaku Corp. (Japan) - Teijin Pharma Limited (Japan) Key Topics Covered: 1. GLOBAL MARKET OVERVIEW 2. MARKET TRENDS AND ISSUES 3. BIOMATERIALS A BRIEF OVERVIEW 4. SEGMENT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT KEY PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 55 (including Divisions/Subsidiaries 60) - The United States (36) - Canada (1) - Japan (3) - Europe (18) - France (1) - Germany (4) - The United Kingdom (5) - Italy (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/hs...llagen_and
AGN: 229.49 (+1.87), ANIK: 41.30 (-0.17)
Don't Discount Bill Ackman
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 11:13AM CST
Originally Published on January 28, 2015 Bill Ackman wears an almost punchably smug expression. He looks as if he thinks that he is the smartest guy in any room. All the more grating is the fact that, in most rooms, he is right. He has reasons to...
ZTS: 45.46 (-0.33), AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), HHC: 144.41 (+6.41), TPRE: 13.91 (+0.03), PAH: 22.68 (+0.14), CP: 186.30 (-0.54), APD: 152.81 (+0.59), GLRE: 31.99 (+0.01)
EQUITY ALERT: Rosen Law Firm Reminds Investors Who Sold Allergan Inc. Stock of the Important February 17, 2015 Class Action Deadline -- AGN
GlobeNewswire - Wed Feb 11, 11:08AM CST
The Rosen Law Firm, a global investor rights firm, reminds all sellers of Allergan Inc. stock (NYSE:AGN) between February 25, 2014 and April 21, 2014 of the important February 17, 2015 lead plaintiff deadline in the class action.
AGN: 229.49 (+1.87)
Allergan Has Returned 35.6% Since SmarTrend Recommendation (AGN)
Comtex SmarTrend(R) - Wed Feb 11, 9:39AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 5 months, Allergan has returned 35.58% as of today's recent price of $226.56.
AGN: 229.49 (+1.87)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
After Yesterday's Rally of 1.54% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Feb 10, 3:47PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $223.62 to a high of $226.76. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $226.20 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 229.49 (+1.87)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
Actavis to Divest U.S. Rights of Doryx to Mayne Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:41PM CST
Actavis (ACT) to divest U.S. rights of Doryx brand to Mayne Pharma, to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
Pfizer Starts Accelerated $5B Share Repurchase Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:43PM CST
Pfizer Inc. (PFE) announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS) whereby it will repurchase $5 billion of its common stock.
AGN: 229.49 (+1.87), GS: 189.00 (-0.78), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Gardy & Notis, LLP Reminds Investors Who Sold Allergan (AGN) Shares Between February 25, 2014 and April 21, 2014 of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
PR Newswire - Tue Feb 10, 12:28PM CST
The securities class action firm Gardy & Notis, LLP, announces that class action litigation has been brought on behalf of those who sold the common stock of Allergan Inc. ("Allergan" (NYSE: AGN) between February 25, 2014 and April 21, 2014, inclusive (the "Class Period" .
AGN: 229.49 (+1.87)
Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 5:04PM CST
Positive news flowed in for Roche (RHHBY) when it announced that the FDA has approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR) in patients suffering from diabetic macular edema (DME).
AGN: 229.49 (+1.87), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Glaxo Submits Another Revolade Application in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:54PM CST
GlaxoSmithKline (GSK) announced that it has submitted another marketing application for Revolade in the EU.
AGN: 229.49 (+1.87), LGND: 55.91 (-0.35), GSK: 47.94 (+1.99)
Global Botulinum Toxin Market
PR Newswire - Mon Feb 09, 12:37PM CST
This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as -
AGN: 229.49 (+1.87)
The Bengtson Center, a Grand Rapids, Michigan, plastic surgery practice, is named one of Allergan's "Top 100"
PRWeb - Mon Feb 09, 11:01AM CST
The Bengtson Center for Aesthetics and Plastic Surgery in Grand Rapids, Michigan, has been named to the Allergan Inc. Top 100 Practices in America list for 2014, earning a No. 90 ranking nationwide. Allergan Inc. is the producer of facial and breast products, including Natrelle(R) breast implants (known as "gummy bear" breast implants), BOTOX(R) Cosmetic, Juvéderm(R) facial filler, and Latisse(R) eyelash enhancement.
AGN: 229.49 (+1.87)
5 Rocket Stocks to Buy in This Misleading Market: LinkedIn, Lululemon and More
at The Street - Mon Feb 09, 6:44AM CST
These stocks have both short-term gain catalysts and longer-term growth prospects.
AGN: 229.49 (+1.87), ATVI: 23.11 (+0.17), LNKD: 269.00 (+1.83), DOW: 49.44 (+0.29), LULU: 65.98 (-0.06)
Loeb adds Citigroup, Alibaba, AIG stakes; drops FedEX
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 6:22PM CST
FDX: 176.47 (+0.17), AGN: 229.49 (+1.87), C: 51.20 (+0.31), EMC: 27.99 (+0.12), AIG: 53.96 (+1.51), BABA: 89.05 (+1.95)
Ackman vs. Icahn: How Two Billionaires, Former Adversaries, Stack Up
at The Street - Fri Feb 13, 10:14AM CST
More than two years have passed since Icahn and Ackman's epic CNBC blowout. Though they've since called a truce, it's worth looking at how these two billionaires stack up today.
AGN: 229.49 (+1.87), HLF: 32.78 (-0.84), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), EBAY: 56.47 (+1.73), GCI: 34.77 (-0.07), IEP: 100.21 (+0.28), MTW: 21.86 (+0.34), AAPL: 127.08 (+0.62)
UPDATE - SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Involving Allergan, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of February 17, 2015
Business Wire - Thu Feb 12, 3:08PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who sold Allergan, Inc. ("Allergan" or the "Company"
(NYSE:AGN) securities between February 25, 2014 and April 21, 2014. AGN: 229.49 (+1.87)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Collagen and HA-Based Biomaterials - Global Strategic Business Report 2015: Increasing Preference for Shorter and Convenient Treatment Options
M2 - Wed Feb 11, 2:30PM CST
Research and Markets (http://www.researchandmarkets.com/research/hsppk2/collagen_and) has announced the addition of the "Collagen and HA-Based Biomaterials - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Collagen and HA-Based Biomaterials in US$ Thousands by the following Product Segments: Collagen-based Biomaterials (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, Wound Dressings), and Hyaluronic Acid-based Biomaterials (Viscosupplements, Viscoelastics, and Facial Aesthetic Dermal Fillers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 55 companies including many key and niche players such as: - Abbott Medical Optics, Inc. (US) - Alcon Laboratories, Inc. (US) - Allergan, Inc. (US) - Anika Therapeutics, Inc. (US) - Bausch & Lomb, Inc. (US) - Collagen Solutions Plc. (UK) - Galderma (Switzerland) - Genzyme (US) - Lifecore Biomedical, LLC (US) - Seikagaku Corp. (Japan) - Teijin Pharma Limited (Japan) Key Topics Covered: 1. GLOBAL MARKET OVERVIEW 2. MARKET TRENDS AND ISSUES 3. BIOMATERIALS A BRIEF OVERVIEW 4. SEGMENT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT KEY PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 55 (including Divisions/Subsidiaries 60) - The United States (36) - Canada (1) - Japan (3) - Europe (18) - France (1) - Germany (4) - The United Kingdom (5) - Italy (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/hs...llagen_and
AGN: 229.49 (+1.87), ANIK: 41.30 (-0.17)
Don't Discount Bill Ackman
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 11:13AM CST
Originally Published on January 28, 2015 Bill Ackman wears an almost punchably smug expression. He looks as if he thinks that he is the smartest guy in any room. All the more grating is the fact that, in most rooms, he is right. He has reasons to...
ZTS: 45.46 (-0.33), AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), HHC: 144.41 (+6.41), TPRE: 13.91 (+0.03), PAH: 22.68 (+0.14), CP: 186.30 (-0.54), APD: 152.81 (+0.59), GLRE: 31.99 (+0.01)
EQUITY ALERT: Rosen Law Firm Reminds Investors Who Sold Allergan Inc. Stock of the Important February 17, 2015 Class Action Deadline -- AGN
GlobeNewswire - Wed Feb 11, 11:08AM CST
The Rosen Law Firm, a global investor rights firm, reminds all sellers of Allergan Inc. stock (NYSE:AGN) between February 25, 2014 and April 21, 2014 of the important February 17, 2015 lead plaintiff deadline in the class action.
AGN: 229.49 (+1.87)
Allergan Has Returned 35.6% Since SmarTrend Recommendation (AGN)
Comtex SmarTrend(R) - Wed Feb 11, 9:39AM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 5 months, Allergan has returned 35.58% as of today's recent price of $226.56.
AGN: 229.49 (+1.87)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
After Yesterday's Rally of 1.54% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Feb 10, 3:47PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $223.62 to a high of $226.76. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $226.20 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 229.49 (+1.87)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
Actavis to Divest U.S. Rights of Doryx to Mayne Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:41PM CST
Actavis (ACT) to divest U.S. rights of Doryx brand to Mayne Pharma, to boost focus on core areas.
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AZN: 69.96 (+0.20)
Pfizer Starts Accelerated $5B Share Repurchase Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:43PM CST
Pfizer Inc. (PFE) announced that it has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS) whereby it will repurchase $5 billion of its common stock.
AGN: 229.49 (+1.87), GS: 189.00 (-0.78), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Gardy & Notis, LLP Reminds Investors Who Sold Allergan (AGN) Shares Between February 25, 2014 and April 21, 2014 of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
PR Newswire - Tue Feb 10, 12:28PM CST
The securities class action firm Gardy & Notis, LLP, announces that class action litigation has been brought on behalf of those who sold the common stock of Allergan Inc. ("Allergan"
(NYSE: AGN) between February 25, 2014 and April 21, 2014, inclusive (the "Class Period" . AGN: 229.49 (+1.87)
Roche's Lucentis Gets FDA Nod for Diabetic Retinopathy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 5:04PM CST
Positive news flowed in for Roche (RHHBY) when it announced that the FDA has approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR) in patients suffering from diabetic macular edema (DME).
AGN: 229.49 (+1.87), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Glaxo Submits Another Revolade Application in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:54PM CST
GlaxoSmithKline (GSK) announced that it has submitted another marketing application for Revolade in the EU.
AGN: 229.49 (+1.87), LGND: 55.91 (-0.35), GSK: 47.94 (+1.99)
Global Botulinum Toxin Market
PR Newswire - Mon Feb 09, 12:37PM CST
This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as -
AGN: 229.49 (+1.87)
The Bengtson Center, a Grand Rapids, Michigan, plastic surgery practice, is named one of Allergan's "Top 100"
PRWeb - Mon Feb 09, 11:01AM CST
The Bengtson Center for Aesthetics and Plastic Surgery in Grand Rapids, Michigan, has been named to the Allergan Inc. Top 100 Practices in America list for 2014, earning a No. 90 ranking nationwide. Allergan Inc. is the producer of facial and breast products, including Natrelle(R) breast implants (known as "gummy bear" breast implants), BOTOX(R) Cosmetic, Juvéderm(R) facial filler, and Latisse(R) eyelash enhancement.
AGN: 229.49 (+1.87)
5 Rocket Stocks to Buy in This Misleading Market: LinkedIn, Lululemon and More
at The Street - Mon Feb 09, 6:44AM CST
These stocks have both short-term gain catalysts and longer-term growth prospects.
AGN: 229.49 (+1.87), ATVI: 23.11 (+0.17), LNKD: 269.00 (+1.83), DOW: 49.44 (+0.29), LULU: 65.98 (-0.06)
